Wednesday, August 12, 2009

Dale Steyn caught in Doping Web


Dale Steyn - the lanky fast bowler from South Africa has been caught in the vicious web of Doping. It is said that he took some painkillers during IPL 2, when he was injured.

"We are aware of the result and submitted a report immediately to the IPL on why this has happened," said Gerald Majola, CSA's chief executive. "There was a marginal increase in the presence of morphine in the sample and that was due to painkillers he took during that period. We are awaiting a reply from the IPL authorities.

Steyn was however out of action for the most part of IPL 2, where he plays for Royal Challengers Bangalore. However, a Royal Challengers Bangalore official said that the franchise had no insight of this development. "Till Sunday night, Royal Challengers had no information or knowledge on this," Prakash Mirpuri, a vice-president of the UB Group, which owns the Bangalore franchise, told Cricinfo. "We can only comment if we receive official communication from CSA/IPL."

Lalit Modi, the IPL commissioner, said Steyn had not failed in any dope test and that the procedure was at the clarification stage. "From what I gather, the agency that conducts these tests for IPL (ITDN) may have asked Cricket South Africa for a clarification on the results of Steyn's test since he is contracted to that board," he said. "The next step is taken only when the agency is not satisfied with the explanation provided. In Steyn's case, this process is at the clarification stage. Officially, the IPL is yet to come into the picture."

Dale had taken a painkiller on the day of the test and the morphine level in his sample was found to be slightly higher (1.1 to 1.3 microgram per ml) than the 1 microgram per ml that is permitted.

Dale Steyn is the 2nd pacer to come under the scrutiny for a failed drug test in the Indian Premier League; Pakistan's pacer Mohammad Asif was banned for a year after testing positive for nandrolone, which is a banned substance, in the inaugural season in 2008.

0 comments:

Post a Comment